Patents by Inventor Marian R. Neutra

Marian R. Neutra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7262270
    Abstract: The present invention provides a fusion protein construct (gp41HA) consisting of the ectodomain of the HIV-1IIIB envelope glycoprotein gp41 fused to a fragment of the influenza virus HA2 hemagglutinin protein. Immunization in-vivo via an intraperitoneal prime followed by intranasal or intragastric boosts with gp41HA induces high concentrations of serum IgG antibodies and fecal IgA antibodies that reacted with gp41 in HIV-1IIIB viral lysate and are cross-reactive with gp41 in HIV-1MN lysate. Followup analyses by indirect immunofluorescence showed that both serum IgG and fecal IgA recognized human peripheral blood mononuclear cells infected with either syncytium-inducing (SI) or non-syncytium-inducing (NSI) North American HIV-1 field isolates, but not uninfected cells.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: August 28, 2007
    Assignee: Children's Medical Center Corporation
    Inventors: Winfried Weissenhorn, David Prashker, legal representative, Nicholas Mantis, Marian R. Neutra, Pamela Kozlowski, Don Wiley, deceased
  • Publication number: 20040096458
    Abstract: The present invention provides a fusion protein construct (gp41HA) consisting of the ectodomain of the HIV-1IIIB envelope glycoprotein gp41 fused to a fragment of the influenza virus HA2 hemagglutinin protein. Immunization in-vivo via an intraperitoneal prime followed by intranasal or intragastric boosts with gp41HA induces high concentrations of serum IgG antibodies and fecal IgA antibodies that reacted with gp41 in HIV-1IIIB viral lysate and are cross-reactive with gp41 in HIV-1MN lysate. Follow up analyses by indirect immunofluorescence showed that both serum IgG and fecal IgA recognized human peripheral blood mononuclear cells infected with either syncytium-inducing (SI) or non-syncytium-inducing (NSI) North American HIV-1 field isolates, but not uninfected cells.
    Type: Application
    Filed: September 5, 2003
    Publication date: May 20, 2004
    Inventors: Winfried Weissenhorn, Don Wiley, Nicholas Mantis, Marian R. Neutra, Pamela Kozlowski
  • Patent number: 6541000
    Abstract: A method for generating antigen-sensitized Ig-A-producing lymphoblasts in a mammal, using an immunogen comprising an antigen or antigen mixture in association with hydroxylated calcium phosphate (hydroxy apatite) is administered to a mucosal surface of the mammal.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: April 1, 2003
    Assignees: President & Fellows of Harvard College, Institut Suisse de Recherche Experimentale sur le Cancer
    Inventors: Helen M. Amerongen, Marian R. Neutra, Jean-Pierre Kraehenbuhl
  • Patent number: 6086881
    Abstract: The present invention is a spatially aligned conjugated composition which comprises at least one chemically modified substance which is immunologically representative of a prechosen infectious agent and provides a chemical constituent for entering into and forming a thioether bond; a plurality of chemically substituted metallic oxide particles which range from about 10-10,000 nanometers and are able to enter into a thioether bond and covalent linkage; and at least one thioether bond and linkage joining the metallic oxide particles in a controlled and spatially aligned manner to the antigen or hapten. The conjugated composition may be alternatively employed as an immunogen; as a vaccine; as a diagnostic tool and reactant; and as an analytical material suitable for testing the pharmacological activity of new compounds.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: July 11, 2000
    Assignee: Children's Medical Center Corp.
    Inventors: Andreas Frey, Marian R. Neutra, Frank A. Robey
  • Patent number: 5443832
    Abstract: A method for generating antigen-sensitized Ig-A-producing lymphoblasts in a mammal, using an immunogen comprising an antigen or antigen mixture in association with hydroxylated calcium phosphate (hydroxy apatite) is administered to a mucosal surface of the mammal.
    Type: Grant
    Filed: April 16, 1990
    Date of Patent: August 22, 1995
    Assignee: Institut Swisse de Recherches Experimentales sur le Cancer
    Inventors: Helen M. Amerongen, Marian R. Neutra, Jean-Pierre Kraehenbuhl